Skip to content

Study · Systematic review · 2026

2 results

Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.

Souza M, Al-Sharif L, Antunes VLJ, Wong SY, Huang DQ, Loomba R

Alimentary pharmacology & therapeutics5 Feb 2026Cited by 6 (Europe PMC)

PMID41645601 (opens in a new tab)DOI10.1111/apt.70565 (opens in a new tab)PepBankPUB-41645601
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In compensated MASH cirrhosis, semaglutide was significantly superior to placebo for MASH resolution in a network meta-analysis, and ranked third by SUCRA (63.88).

    In plain wordsIn people with advanced fatty liver disease (MASH cirrhosis), semaglutide cleared MASH more often than placebo in a pooled comparison of trials.

    Peptide
    Semaglutide
    Outcome
    IncreaseMASH resolution
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    63.88 score
    semaglutide, MASH resolution

    Source sentences

    Summary
    and semaglutide were significantly superior to placebo.
    2 context sentences
    Summary · context
    and semaglutide (SUCRA: 63.88) had the highest probability of ranking best for MASH resolution.
    Summary · context
    Nine RCTs with 3266 participants met the eligibility criteria.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In compensated MASH cirrhosis, the regimen semaglutide + cilofexor + firsocostat was significantly superior to placebo for MASH resolution (SUCRA 74.07).

    In plain wordsIn people with advanced fatty liver disease (MASH cirrhosis), a three-drug regimen that includes semaglutide cleared MASH more often than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseMASH resolution
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver

    Measurements

    SUCRA
    74.07 score
    semaglutide + cilofexor + firsocostat, MASH resolution

    Source sentences

    Summary
    semaglutide + cilofexor + firsocostat and semaglutide were significantly superior to placebo.
    2 context sentences
    Summary · context
    semaglutide + cilofexor + firsocostat (SUCRA: 74.07)
    Summary · context
    Nine RCTs with 3266 participants met the eligibility criteria.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.